35
Participants
Start Date
May 31, 2007
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
ZK-EPO
Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Collaborators (1)
Bayer
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER